Phage Therapy in Clinical Practice: Treatment of Human Infections

被引:455
|
作者
Kutter, Elizabeth [1 ]
De Vos, Daniel [2 ]
Gvasalia, Guram [3 ]
Alavidze, Zemphira [4 ]
Gogokhia, Lasha [5 ]
Kuhl, Sarah [6 ]
Abedon, Stephen T. [7 ]
机构
[1] Evergreen State Coll, Lab 1, Olympia, WA 98505 USA
[2] Queen Astrid Mil Hosp, Lab Mol & Cellular Technol, Burn Wound Ctr, B-1120 Brussels, Belgium
[3] Tbilisi State Med Univ, Dept Gen Surg, GE-0160 Tbilisi, Georgia
[4] Eliava Inst Bacteriophages Microbiol & Virol, Lab Phage Morphol & Biol, GE-0160 Tbilisi, Georgia
[5] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA
[6] VA No Calif Hlth Care Syst, Martinez, CA 94553 USA
[7] Ohio State Univ, Dept Microbiol, Mansfield, OH 44906 USA
关键词
Bacteriophages; burn care; Eliava Institute; Hirszfeld Institute; intestiphage; osteomyelitis treatment; phage therapy; purulent infections; pyophage; wound care; SUPPURATIVE BACTERIAL-INFECTIONS; BACTERIOPHAGE TREATMENT; PSEUDOMONAS-AERUGINOSA; DETAILED EVALUATION; SUSTAINED-RELEASE; BURN WOUNDS; SEPTICEMIA; TRANSPLANTATION; PENETRATION; CHILDREN;
D O I
10.2174/138920110790725401
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phage therapy is the application of bacteria-specific viruses with the goal of reducing or eliminating pathogenic or nuisance bacteria. While phage therapy has become a broadly relevant technology, including veterinary, agricultural, and food microbiology applications, it is for the treatment or prevention of human infections that phage therapy first caught the world's imagination - see, especially, Arrowsmith by Sinclair Lewis (1925) - and which today is the primary motivator of the field. Nonetheless, though the first human phage therapy took place in the 1920s, by the 1940s the field, was in steep decline despite early promise. The causes were at least three-fold: insufficient understanding among researchers of basic phage biology; over exuberance, which led, along with ignorance, to carelessness; and the advent of antibiotics, an easier to handle as well as highly powerful category of antibacterials. The decline in phage therapy was neither uniform nor complete, especially in the former Soviet Republic of Georgia, where phage therapy traditions and practice continue to this day. In this review we strive toward three goals: 1. To provide an overview of the potential of phage therapy as a means of treating or preventing human diseases; 2. To explore the phage therapy state of the art as currently practiced by physicians in various pockets of phage therapy activity around the world, including in terms of potential commercialization; and 3. To avert a recapitulation of phage therapy's early decline by outlining good practices in phage therapy practice, experimentation, and, ultimately, commercialization.
引用
收藏
页码:69 / 86
页数:18
相关论文
共 50 条
  • [1] Phage therapy for the treatment of human intestinal bacterial infections: soon to be a reality?
    Brussow, Harald
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 11 (09) : 785 - 788
  • [2] Constructing and Characterizing Bacteriophage Libraries for Phage Therapy of Human Infections
    Gibson, Shelley B.
    Green, Sabrina I.
    Liu, Carmen Gu
    Salazar, Keiko C.
    Clark, Justin R.
    Terwilliger, Austen L.
    Kaplan, Heidi B.
    Maresso, Anthony W.
    Trautner, Barbara W.
    Ramig, Robert F.
    FRONTIERS IN MICROBIOLOGY, 2019, 10
  • [3] Considerations for the Use of Phage Therapy in Clinical Practice
    Suh, Gina A.
    Lodise, Thomas P.
    Tamma, Pranita D.
    Knisely, Jane M.
    Alexander, Jose
    Aslam, Saima
    Barton, Karen D.
    Bizzell, Erica
    Totten, Katherine M. C.
    Campbell, Joseph L.
    Chan, Benjamin K.
    Cunningham, Scott A.
    Goodman, Katherine E.
    Greenwood-Quaintance, Kerryl E.
    Harris, Anthony D.
    Hesse, Shayla
    Maresso, Anthony
    Nussenblatt, Veronique
    Pride, David
    Rybak, Michael J.
    Sund, Zoe
    van Duin, David
    Van Tyne, Daria
    Patel, Robin
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (03)
  • [4] Phage Therapy as a Novel Strategy in the Treatment of Urinary Tract Infections Caused byE. Coli
    Zalewska-Piatek, Beata
    Piatek, Rafal
    ANTIBIOTICS-BASEL, 2020, 9 (06): : 1 - 20
  • [5] Phage Therapy as an Alternative Treatment Modality for Resistant Staphylococcus aureus Infections
    Atshan, Salman Sahab
    Hamat, Rukman Awang
    Aljaberi, Musheer A.
    Chen, Jung-Sheng
    Huang, Shih-Wei
    Lin, Chung-Ying
    Mullins, Benjamin J.
    Kicic, Anthony
    ANTIBIOTICS-BASEL, 2023, 12 (02):
  • [6] Reassessment of Historical Clinical Trials Supports the Effectiveness of Phage Therapy
    Marongiu, Luigi
    Burkard, Markus
    Lauer, Ulrich M.
    Hoelzle, Ludwig E.
    Venturelli, Sascha
    CLINICAL MICROBIOLOGY REVIEWS, 2022, 35 (04)
  • [7] Exploring the whole standard operating procedure for phage therapy in clinical practice
    Cui, Zelin
    Guo, Xiaokui
    Feng, Tingting
    Li, Li
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)
  • [8] Pharmacokinetic and Pharmacodynamic Obstacles for Phage Therapy From the Perspective of Clinical Practice
    Miedzybrodzki, Ryszard
    Kasprzak, Hubert
    Letkiewicz, Slawomir
    Rogoz, Pawel
    Zaczek, Maciej
    Thomas, Jamon
    Gorski, Andrzej
    CLINICAL INFECTIOUS DISEASES, 2023, 77 : S395 - S400
  • [9] The Future of Clinical Phage Therapy in the United Kingdom
    Jones, Joshua D. D.
    Trippett, Clare
    Suleman, Mehrunisha
    Clokie, Martha R. J.
    Clark, Jason R. R.
    VIRUSES-BASEL, 2023, 15 (03):
  • [10] Phage therapy to treat cystic fibrosis Burkholderia cepacia complex lung infections: perspectives and challenges
    Canning, Jack S.
    Laucirica, Daniel R.
    Ling, Kak-Ming
    Nicol, Mark P.
    Stick, Stephen M.
    Kicic, Anthony
    FRONTIERS IN MICROBIOLOGY, 2024, 15